Lovastatin NDC 51407-252

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-252Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0252Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-252-10	51407025210	1000 TABLET in 1 BOTTLE (51407-252-10)Marketed from Aug 20, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lovastatin
Generic name (nonproprietary): lovastatin
Active ingredients: Lovastatin — 20 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075551
Marketing start: Dec 17, 2001
Listing expires: Dec 31, 2026
Other FDA classes: Hydroxymethylglutaryl-CoA Reductase Inhibitors (Mechanism)
Identifiers: Product ID 51407-252_46049ec7-69c6-fab7-e063-6294a90acd9bSPL ID 46049ec7-69c6-fab7-e063-6294a90acd9bSPL set ID 91332c54-1a27-4e6b-e053-2a95a90a42cdRxCUI 197903, 197904, 197905UNII 9LHU78OQFD
Pharmacologic class: HMG-CoA Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407025210 followed by a unit qualifier and the quantity

Package 51407-0252-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 15, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduc…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)